Literature DB >> 29192558

Spleen tyrosine kinase inhibition: a new promising approach to chronic and refractory immune thrombocytopenia.

Pasquale Niscola1, Laura Scaramucci1, Marco Giovannini1.   

Abstract

Entities:  

Keywords:  ITP; chronic adult immune thrombocytopenia; fostamatinib

Mesh：

Substances：

Year:  2018        PMID： 29192558     DOI： 10.2217/imt-2017-0141

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


× No keyword cloud information.
  4 in total

1.  Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk.

Authors:  Amit R Mehta; Aron Kefela; Charina Toste; Donald Sweet
Journal:  Acta Haematol       Date:  2021-12-14       Impact factor: 3.068

2.  Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia.

Authors:  Ralph Boccia; Nichola Cooper; Waleed Ghanima; Michael A Boxer; Quentin A Hill; Michelle Sholzberg; Michael D Tarantino; Leslie K Todd; Sandra Tong; James B Bussel
Journal:  Br J Haematol       Date:  2020-07-23       Impact factor: 6.998

Review 3.  Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.

Authors:  Nicola Vianelli; Giuseppe Auteri; Francesco Buccisano; Valentina Carrai; Erminia Baldacci; Cristina Clissa; Daniela Bartoletti; Gaetano Giuffrida; Domenico Magro; Elena Rivolti; Daniela Esposito; Gian Marco Podda; Francesca Palandri
Journal:  Ann Hematol       Date:  2022-02-24       Impact factor: 4.030

4.  Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.

Authors:  Kate McKeage; Katherine A Lyseng-Williamson
Journal:  Drugs Ther Perspect       Date:  2018-08-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.